Last reviewed · How we verify
Salbutamol plus Ipratropium Bromide
At a glance
| Generic name | Salbutamol plus Ipratropium Bromide |
|---|---|
| Sponsor | Hat Yai Medical Education Center |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Magnesium Trial in Acute Asthma in Emergency Department (PHASE3)
- Nebulized Ketamine Plus Standard Care vs. Standard Care Alone in Moderate to Severe Asthma Exacerbations (PHASE2)
- The Effect of Nebulized Epinephrine in Asthma Exacerbation in Pediatric Age Group With the Standard Treatment Compared to Standard Treatment Using Improvement PRAM Score as a Primary Outcome (PHASE4)
- Neural Respiratory Drive of Patients With Chronic Obstructive Pulmonary Disease (NA)
- A Comparative Study of Adding Ipratropium to Salbutamol for the Treatment of Asthma Attack in Children (PHASE4)
- Differential Mechanisms of Dyspnea Relief in Advanced COPD: Opiates vs. Bronchodilators (PHASE4)
- Role of Parasympathetic Activity in Mild to Severe Asthma With Fixed Airway Obstruction (PARASMA Study) (NA)
- Prehospital Non-invasive Ventilation for Acute Exacerbation of Chronic Obstructive Pulmonary Disease (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: